SCHEDULE: Vanguard Group Shifts Chemours Ownership Reporting

The Vanguard Group reported zero beneficial ownership in Chemours Co/The following an internal realignment that disaggregated its reporting.

Summary

• The Vanguard Group, Inc. filed an Amendment No. 11 to Schedule 13G regarding its beneficial ownership in Chemours Co/The.
• As of the filing, The Vanguard Group reports 0.00 shares beneficially owned, representing 0% of the class of Common Stock.
• This change is due to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.
• The subsidiaries and/or business divisions will continue to pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Chemours Co/The, as it primarily concerns an internal reporting change by The Vanguard Group rather than a change in investment strategy or a direct assessment of Chemours' performance.

Future Outlook

The filing indicates that Vanguard's subsidiaries will continue to pursue the same investment strategies as previously, but their beneficial ownership will now be reported separately.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that this filing reflects a procedural change in how a major institutional investor, The Vanguard Group, reports its holdings, rather than a strategic divestment from Chemours Co/The. Such internal realignments are not uncommon among large asset managers seeking to optimize reporting structures or comply with specific regulatory interpretations, as indicated by the reference to SEC Release No. 34-39538.

Stakeholder Impact

• Shareholders of Chemours Co/The: The direct impact is minimal as the underlying investment strategy of Vanguard's subsidiaries remains unchanged, only the reporting entity for beneficial ownership has shifted.
• The Vanguard Group: This realignment impacts its internal reporting structure and compliance procedures.

Key Dates

Recommendation

The filing details an internal reporting realignment by The Vanguard Group, resulting in a change in how their beneficial ownership in Chemours Co/The is reported. It does not indicate a strategic divestment or a change in investment thesis regarding Chemours, nor does it provide new information about Chemours' operational or financial performance. Therefore, it offers no basis for a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Chemours Co, The Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, Investment Management, Corporate Governance, Ownership Change, Realignment